Wemade Wins Copyright Dispute Over Legend of Mir 2 Against Actoz Soft in Appeals Court

Reporter Kim Jisun / approved : 2025-07-14 03:53:43
  • -
  • +
  • 인쇄

Photo = Yonhap news

 

 

[Alpha Biz= Kim Jisun] Wemade has won the appellate retrial in its long-standing copyright dispute with Actoz Soft over the hit MMORPG Legend of Mir 2. The Seoul High Court dismissed Actoz Soft’s claims in full and upheld Wemade’s position regarding both copyright succession and licensing rights in China.



This retrial followed a June 2024 ruling by the Supreme Court of Korea, which had returned the case to the appellate court for reexamination under Chinese law, particularly concerning:



Whether copyright infringement occurred in China, and

The legitimacy of Wemade’s copyright succession via a corporate spin-off.



The Seoul High Court ruled that even under Chinese legal standards, Wemade’s transfer of Legend of Mir 2 intellectual property (IP) to its subsidiary Wemade IP through a physical spin-off was valid and lawful. As a result, the legitimacy of Mir-related IP licensing agreements in China was also upheld.



In its ruling, the court rejected Actoz Soft’s claim that licensing revenue should be split 50:50, instead maintaining the 80:20 revenue share in favor of Wemade—a ratio agreed upon by both parties in a prior settlement. Wemade had already paid approximately KRW 4.5 billion in royalties to Actoz Soft in 2019 under this agreement.



This decision strengthens Wemade’s legal standing and licensing rights for Legend of Mir 2 in the Chinese market, one of the world’s largest for online games.

 

 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

어플

주요기사

NAVER Secures 60,000 NVIDIA Blackwell GPUs to Lead Industrial AI Innovation2025.11.01
Shinhan Investment Raises LG Innotek Target Price to ₩280,000 on Earnings Recovery and 2025 Growth Outlook2025.10.31
Woori Bank Sanctioned by Financial Supervisory Service for Delayed Reporting of Overseas Regulatory Actions2025.10.31
Samyang Foods Raises U.S. Supply Prices for Buldak Ramen Amid Tariff Impact2025.10.31
NH Investment & Securities Suspends IB Executive Under Investigation for Alleged Insider Trading2025.10.31
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사